Abstract
Objectives: The administration of gemcitabine (Gem) as postoperative adjuvant chemotherapy for biliary tract cancer was examined in consideration of tolerability. Method: Thirty cases of resected biliary tract cancer are randomly assigned to either a standard schedule or a bi-weekly schedule of gemcitabine. The primary endpoint was the compliance rate for 6 courses, and the secondary end-point was 3-year overall survival time, disease-free survival and adverse events. Results: Dose Intensity was significantly high and adverse events was more frequent in the standard group. But the compliance rate, the mean overall survival time and the disease free time were not different in these two groups. Conclusion: It was suggested that the bi-weekly schedule could be considered a choice for the patients who had difficulty with the standard schedule of gemcitabine.
